Healthcare Unusual Volume: Edwards Lifesciences Corp (NYSE:EW), Allergan (NYSE:AGN), Akebia Therapeutics (NASDAQ:AKBA), Acorda Therapeutics (NASDAQ:ACOR)



Edwards Lifesciences Corp (NYSE:EW) climbed 11 percent after the company won a court ruling that limited the sale of Medtronic’s (MDT) CoreValve system in the US. Edwards Lifesciences Corp (NYSE:EW) stock performance was 11.00% in last session and finished the day at $81.00. Traded volume was 7.23million shares in the last session and the average volume of the stock remained 1.36million shares. The beta of the stock remained 0.47. Edwards Lifesciences Corp (NYSE:EW) insider ownership is 0.50%.

Jefferies downgraded the stock to “hold” from “buy,” a session after Johnson & Johnson said it won’t develop an anti-wrinkle cream to rival Allergan, Inc.’s (NYSE:AGN) Botox. Allergan, Inc. (NYSE:AGN) rose 2.55 percent to $123.97 Monday on volume of 7.18million shares. The intra-day range of the stock was $120.72 to $124.46. Allergan, Inc. (NYSE:AGN) has a market capitalization of $37.08billion.

Akebia Therapeutics Inc (NASDAQ:AKBA), a biopharmaceutical company, was initiated with a Buy rating and a price target of $28.00 per share by brokerage firm UBS. Akebia Therapeutics Inc (NASDAQ:AKBA)’s stock on Apr 14, 2014 reported a increase of 25.39% to the closing price of $21.14. Its fifty two weeks range is $16.41 -$28.50. The total market capitalization recorded $409.76million. The overall volume in the last trading session was 3.07million shares. In its share capital, AKBA has 20.26million outstanding shares.

Acorda Therapeutics Inc (NASDAQ:ACOR) Shares get upgraded to Outperform from Perform at FBR Capital, which takes its target price to $47 from $30. Plumiaz, to treat epilepsy seizures, offers promise, the bank believes. On Monday, shares of Acorda Therapeutics Inc (NASDAQ:ACOR) advanced 1.93% to close the day at $35.87. Company return on investment (ROI) is 4.00% and its monthly performance is recorded as -3.81%. Acorda Therapeutics Inc (NASDAQ:ACOR) quarterly revenue growth is 20.49%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone